Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $110

Canaccord Genuity analyst Edward Nash has maintained a Buy rating on Corcept Therapeutics (NASDAQ: CORT) and increased the price target from $100 to $110.